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Abstract
Background: Mitochondrial diseases, also known as oxidative phosphorylation (OXPHOS) disorders, with a prevalence
rate of 1:5000, are the most frequent inherited metabolic diseases. Leigh Syndrome French Canadian type (LSFC), is
caused by mutations in the nuclear gene (2p16) leucine-rich pentatricopeptide repeat-containing (LRPPRC). It is an
autosomal recessive neurogenetic OXPHOS disorder, phenotypically distinct from other types of Leigh syndrome, with
a carrier frequency up to 1:23 and an incidence of 1:2063 in the Saguenay-Lac-St Jean region of Quebec. Recently,
LSFC has also been reported outside the French-Canadian population.
Patient presentation: We report a male Italian (Sicilian) child, born preterm at 28 + 6/7 weeks gestation, carrying a novel
LRPPRC compound heterozygous mutation, with facial dysmorphisms, neonatal hypotonia, non-epileptic paroxysmal
motor phenomena, and absent sucking-swallowing-breathing coordination requiring, at 4.5months, a percutaneous
endoscopic gastrostomy tube placement. At 5months brain Magnetic Resonance Imaging showed diffuse cortical
atrophy, hypoplasia of corpus callosum, cerebellar vermis hypoplasia, and unfolded hippocampi. Both auditory and visual
evoked potentials were pathological. In the following months Video EEG confirmed the persistence of sporadic non
epileptic motor phenomena. No episode of metabolic decompensation, acidosis or ketosis, frequently observed in LSFC
has been reported. Actually, aged 14months corrected age for prematurity, the child shows a severe global
developmental delay. Metabolic investigations and array Comparative Genomic Hybridization (aCGH) results were normal.
Whole-exome sequencing (WES) found a compound heterozygous mutation in the LRPPRC gene, c.1921–7A > G and
c.2056A > G (p.Ile686Val), splicing-site and missense variants, inherited from the mother and the father, respectively.
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Conclusions: We first characterized the clinical and molecular features of a novel LRPPRC variant in a male Sicilian child
with early onset encephalopathy and psychomotor impairment. Our patient showed a phenotype characterized by a
severe neurodevelopmental delay and absence of metabolic decompensation attributable to a probable residual
enzymatic activity. LRPPRC is a rare cause of metabolic encephalopathy outside of Québec. Our patient adds to and
broaden the spectrum of LSFC phenotypes. WES analysis is a pivotal genetic test and should be performed in infants and
children with hypotonia and developmental delay in whom metabolic investigations and aCGH are normal.
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Introduction
Leigh syndrome, French-Canadian type (LSFC, MIM#220
111) is a neurogenetic degenerative disorder caused by mu-
tations in the nuclear gene leucine-rich pentatricopeptide
repeat-containing (LRPPRC) localized on 2p16. It is pheno-
typically distinct from other types of Leigh syndrome, for
the possible early occurrence of fatally severe metabolic cri-
ses [1]. As a result of a founder effect, this rare monogenic
autosomal recessive mitochondrial disease is more prevalent
in the Saguenay-Lac-St Jean (SLSJ) region of Quebec [2]
with a carrier frequency up to 1:23 adults and an incidence
of 1:2063 live births [2, 3]. LRPPRC is a multifunctional pro-
tein belonging to a family of pentatricopeptide repeat (PPR)
proteins containing a canonical 35 residue repeat motif that
confer an ability to recognize RNA substrates regulating
several post-transcriptional processes such as RNA editing,
RNA stability or RNA degradation [4, 5]. Most LSFC pa-
tients are homozygous for an A354V substitution that
causes a decrease in the expression of the LRPPRC protein
[6]. Biochemically, LSFC is characterized by a severe
cytochrome-c oxidase (COX) deficiency in the brain and
liver, while in other tissues, such as kidneys, skeletal muscle,
and heart, COX activity is affected to a lesser extent (50–
80% residual activity) [1, 2]. In recent years, novel disease-
causing mutations have been reported from some unrelated
families outside the French-Canadian population [6]. Early
onset, from birth to 5months, has been described as charac-
terized by neonatal neurological findings including beyond
hypotonia, transient tachypnea, poor sucking, tremor, along
with acute metabolic decompensation including acidosis
and ketosis, described as frequently fatal, and stroke-like ep-
isodes [1, 7]. In survivors a severe neurological impairment
is described including: dystonia, ataxia, dysphagia, strabis-
mus and seizures. Brain imaging has evidenced in some pa-
tients, cerebral malformations (cerebellar hypoplasia, gyral
abnormalities, and hippocampal abnormalities), leukoence-
phalopathy, and progressive degenerative involvement of
brainstem and basal ganglia [6, 8]. Consistently dysmorphic
cranio-facial features as prominent forehead, anteverted
nares, arched eyebrows hypertelorism, with varying degrees
of midfacial hypoplasia have been described [2]. Moreover,
polysyndactyly, complex congenital heart disease,
hypertrophic cardiomyopathy, hypospadias and anteriorly
placed anus have been sporadically reported [6].
Patient presentation
Since our patient was born preterm, in this report we have
referred to both a chronological age (CrA) and a corrected
age for prematurity (CA), considering the difference of 78
days to reach the 280 days length of full-term pregnancy.
The proband was the second child of healthy and non-
consanguineous Italian parents from Sicily. He was born
preterm, at 28 + 6/7 weeks after a naturally conceived
pregnancy, by cesarean section for premature rupture of
membranes, chorioamnionitis and fetal distress. Apgar
scores were 7 and 7, at 1 and 5min, respectively. At birth,
his weight was 1360 g (80th centile), length 40 cm (86th
centile), and occipitofrontal circumference (OFC) 28.4 cm
(89th centile). On physical examination, he showed dys-
morphic features: prominent forehead, hypertelorism,
broad nasal bridge, anteverted nares, flattened philtrum,
thin upper lip, and high-arched palate. Neurological exam-
ination revealed, marked generalized hypotonia with pres-
ence of deep tendon reflexes, depressed neonatal reflexes,
poor spontaneous motility, right exophoria, disconjugated
eye movements and weak cry (Fig. 1). Brain ultrasound
(US) showed normal corpus callosum and mild dilatation
of the left lateral ventricle. He had poor respiratory adap-
tation with tachypnea needing non-invasive ventilatory
support from birth to 3months CrA (15 days CA). From
birth repeated Video-EEG monitoring showed sporadic
spontaneous as well as provoked clonic and spontaneous
motor paroxysms involving limbs, without concomitant
EEG discharge (Fig. 2). He necessitated of frequent oro-
pharyngeal aspirations due to swallowing dysfunction, an
early sign of incoordination of sucking-swallowing and
breathing. These findings suggested, in relation to failure
to thrive and frequent episodes of reflux associated with
apnea, to convert to a nasogastric tube feeding regimen
until insertion, at 4.5 months CrA, of a percutaneous
endoscopic gastrostomy (PEG). At 5months of CrA, cor-
responding to 2.5 months CA, a brain MRI revealed a mild
diffuse cerebral atrophy, hypoplasia of the corpus callo-
sum, cerebellar vermis hypoplasia (Fig. 3) and bilateral in-
complete hippocampal inversion (Fig. 4). Visual evoked
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potentials (VEP) recorded to binocular flash stimulation
showed a delayed P100 latency (240msec in right hemi-
sphere, 270msec in left hemisphere), and brainstem audi-
tory evoked potentials (BAEP) showed increased hearing
threshold (60 dB) in the right ear and absence response
even at high-intensity stimulation (110 dB) in the left ear.
Extended newborn screening for inherited metabolic dis-
orders and aCGH were negative. Thus, on the basis of the
clinical evolution suggesting a mitochondrial encephalop-
athy, a further metabolic diagnostic work-up was carried
on. Plasma amino acids, acylcarnitines and biotinidase
were normal, while urinary organic acids analysis showed
marked increase of 4-OH phenylacetic acid, along with a
moderate increase of phenylpyruvic and mild increase of
ethylmalonic and fumaric acids. Thus, at 5months CA,
WES analysis was performed. The genomic sequencing,
Fig. 1 Neonatal dysmorphic facial features: prominent forehead, hypertelorism, broad nasal bridge, flattened philtrum, thin upper lip. Right
exophoria is present
Fig. 2 Awake video-EEG at 2.5 months CA: spontaneous motor paroxysm involving left harm without concomitant EEG discharge
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Fig. 3 Brain MRI T2 sagittal image: mild diffuse cerebral atrophy, hypoplasia of the corpus callosum (white arrow), cerebellar vermis hypoplasia (white circle)
Fig. 4 Brain MRI T2 coronal image: incomplete bilateral hippocampal inversion (white arrows) and left lateral ventricle dilatation
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followed by direct sequencing, found and confirmed that
the patient carried a compound heterozygous mutation in
the LRPPRC gene, c.1921–7A >G and c.2056A >G
(p.Ile686Val), splicing-site and missense variants, inherited
from the mother and the father, respectively. The mutation
of maternal origin and has not hitherto been described in
the literature. Therefore, based on current knowledge, the
variant can be classified as likely pathogenic (class IV). The
second variant of paternal origin consisted in a replace-
ment of an adenine with a guanine in position 2056 of the
codon 686, determining the substitution of isoleucine with
valine. This variant has not been described in the literature
too, and according to current knowledge, can be classified
of uncertain significance (class III). Parents refused any fur-
ther invasive investigation for the execution of functional
studies that could demonstrate COX activity deficit. Thus,
to assess the functional effect of mRNA transcripts, we per-
formed a reverse transcription-polymerase chain reaction
(RT-PCR) that demonstrated the deletion of 45 base pairs
in the exon 19 with a likely deletion of 15 amino acids in
the encoded protein. He is currently 14months CA, his
weight is 5.500 g (− 5.4 SD), length 65 cm (− 5.2 SD) and
OFC 40.6 cm (− 4.6 SD). Owing to the severe generalized
hypotonia he has to lie in bed with nasal cannula O2 sup-
plementation. He shows only sporadic movements of head
rotation without focusing on a nearby object. Neither
vocalization nor blinking reaction to bell and rattle are
present. He is unable to move his limbs and maintains
adducted thumbs in both hands (Fig. 5). Nutritional supply
with protein hydrolysate, MCT, Vitamin supplements, L-
carnitine and glycopyrrolate for drooling are provided by
PEG. However, he has never experienced to date episodes
of acute ketosis, glycemic derangements, or any acute
stroke like events. A home rehabilitation treatment has
been started.
Discussion and conclusions
In 1994, Hou first identified the LRPPRC gene, which
encodes for a protein containing 35 amino acid repeat
motifs [9], that conferring an ability to recognize RNA
substrates, regulate a number of post-transcriptional
processes such as RNA editing, stability or degradation
[4]. Next generation sequencing, including WES, Whole
Genome Sequencing and RNA sequencing, has revolu-
tionized the diagnostic approach of rare genetic disor-
ders, making it possible to undertake a phenotyping
driven by the results from genetic markers, called “re-
verse phenotyping” approach [10, 11].
In our patient we adopted a “reverse phenotyping”
approach, since WES analysis through the identification of
novel LRPPRC compound heterozygous mutations, made
it possible to refine the patient phenotype and the diagno-
sis of LSFC.
We identified a novel pathogenic compound heterozy-
gous LRPPRC mutation in a male Italian child from Sicil-
ian parents, consisting of a maternal splicing site (class IV)
and a paternal missense (class III) variant. Thus, our pro-
band did not carry, the most reported French-Canadian
founder mutation. However, his clinical features resembled
LSFC in many aspects including severe global neurodeve-
lopmental impairment, generalized hypotonia, dystonia,
dysphagia, exophoria, visual and hearing impairment and
post-natal growth deficiency. In our patient brain anomal-
ies and reduced neuronal cell proliferation leading to
cortical atrophy, hypoplasia of corpus callosum, cerebellar
vermis hypoplasia, left lateral ventricular dilatation,
Fig. 5 Patient 14 months CA: Bilateral adducted thumbs
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unfolded hippocampi, have been evidenced by brain MRI.
We suppose that the described involvement of basal gan-
glia, and midbrain, reported in some patients was not still
present probably owing to the younger age [6]. Neither epi-
sodes of severe (sometimes fatal) lactic acidosis, nor ketosis
or hyperglycemia were present in our patient, whose lactic
acid levels maintained from birth levels < 2.5mmol/l. Urin-
ary organic acids analysis showed marked increase of 4-OH
phenylacetic acid, along with a moderate increase of phe-
nylpyruvic and mild increase of ethylmalonic and fumaric
acids. These results were not suggestive of mitochondrial
deficit. Since in our patient we have not performed West-
ern blot analyses for dosing protein levels of subunits of
mitochondrial respiratory chain complexes, we can only
speculate that a less severe compound heterozygous muta-
tion could have avoided, to date, a fatal metabolic crisis, as
well as the onset of left ventricle cardiomyopathy frequently
found by others [6]. Indeed, these last deleterious effects
have been found to be more frequently related to the LRPP
RC A354V founder mutation, responsible for an increased
mitochondrial vulnerability and nutrient-induced cytotox-
icity [12]. Moreover, different dose effects could also result
from functional differences in gene expression depending
on the parental origin of the single mutation, as recently de-
scribed in other neurodevelopmental disorders [13].
A pathogenic link between LSFC and Neurofibromatosis
type 1 (NF1), a clinically heterogeneous, neurocutaneous
genetic disorder [14], has been recently found studying
the RNA granules. The RNA granules play a key role in
regulating de novo protein synthesis in a temporal and
spatial manner by microtubule-dependent, motor protein-
driven transport of mRNA cargoes to subcellular sites of
requirement [15]. The tubulin binding domain of NF1 is a
binding partner of the LRPPRC protein and both proteins
complex with Kinesin 5B, Staufen1, hnRNP A2, and Mye-
lin Basic Protein mRNA, likely in RNA granules. These
findings provide clues to how loss or mutation of NF1 and
LRPPRCmay contribute to the wide range of clinical man-
ifestations reported in both condition [16]. Despite signifi-
cant advances in understanding the molecular genetics of
LSFC, the pathogenic mechanisms (precise molecular
ones through which LRPPRC stabilizes mitochondrial
transcripts) underlying this severe and unpredictable
disease remain unclear. In most mitochondrial diseases,
impaired capacity to generate ATP is believed to be the
main culprit and mitochondria play a central role in other
numerous vital processes (including triggering of pro-
grammed cell death), all of which could contribute to dys-
function and death, particularly when cells are faced with
stressful conditions. On the other hand, a compensatory
mechanism to preserve ATP level and consisting in the
activation of the mTORC1 pathway and its downstream
target HIF-1α/PDHK1n LSFC fibroblasts has been re-
cently described [17].
Effective treatment strategies for these patients are lack-
ing. Recent progress achieved in pharmacogenomics
might provide an effective treatment targeting potential
consequences of COX deficiency such as impaired elec-
tron transport chains flux, oxidative stress, mitochondrial
cell death signaling, and accumulation of toxic metabolites
with interesting concerns about the nature of the diets,
particularly excess fat intake, as well as on the use of anti-
oxidants in patients with LSFC and, possibly, other COX
defects have been raised. Indeed, Burelle et al. have dem-
onstrate the protective effect of compounds (methylene
blue and dinitrophenol) that promote flux through the
electron transport chain independent of phosphorylation,
and that modulate fatty acid (L-carnitine) or Krebs cycle
metabolism (propionate), while antioxidants (resveratrol,
idebenone, Nacetyl cysteine) exacerbate palmitate plus
lactate-induced cell death [12].
In this report we have described the clinical and genetic
aspects of a novel compound heterozygous mutation of
LRPPRC in an Italian male child with early onset LSFC
characterized by severe neurologic involvement and facial
dysmorphic features. The absence of early metabolic crisis
or relevant lactic acidosis broaden the spectrum of pheno-
types of LSFC. Our patient is one of the few reported out-
side of the French-Canadian population and the first, to
our knowledge, observed in Italy. Integrated and family
centered model of care for potential end-of-life patholo-
gies should implement protocols that reduce unreasonable
therapeutic obstinacy [18] and offer parents acceptance
and commitment based coping strategies [19]. WES ana-
lysis, a pivotal genetic test for early diagnosis, prognostic
definition and accurate genetic counselling, should be per-
formed in infants and children with hypotonia and devel-
opmental delay in whom metabolic investigations are
normal and chromosomal aneuploidy, microdeletions and
microduplications have been excluded by aCGH. More-
over, it has been recently proposed as a powerful tool for
the diagnostic evaluation of critically ill infants with sus-
pected monogenic disorders in the Neonatal and Pediatric
Intensive Care Units and its use has a notable effect on
clinical decision-making process [20].
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